We analyzed data from historical controls treated with meglumine antimoniate to compare the frequency of adverse events observed in patients with cutaneous leishmaniasis treated with the same dose of meglumine antimoniate contaminated with heavy metals in an endemic area of the State of Bahia, Brazil. Group A patients were treated in 2000 with the drug produced by Eurofarma Laborat rios Ltda., ...

We report in this study the in vivo efficacy of nine 2-substituted quinolines on the Leishmania amazonensis cutaneous infection murine model and on the Leishmania infantum and Leishmania donovani visceral infection murine models. In the case of the L. amazonensis model, quinolines were administered orally at 25 mg/kg twice daily for 15 days. Quinolines 1, 2, 3, and 7 reduced by 80 to 90% the pa...

New therapeutic alternatives against leishmaniasis remain a priority. The activity of azithromycin against Leishmania (Leishmania) major has been previously demonstrated. Different responses among species of Leishmania make species-specific drug screening necessary. The activity of azithromycin against Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis was evaluated in go...

acute cutaneous leishmaniasis(ACL) is an endemic disease in developing countries.the first line drug for treatment of ACL.according to WHO recommendation,is the pentavalent antimony compounds such as meglumine antimoniate(Glucantime{SB}).high cost ,side effects,multiple injections and incomplete efficacy are limitations of this therapy.we evaluated the efficacy of intralesional(IL) injection of...

Aim: To see the efficacy of meglumine antimoniate alone in comparison with combination and CO2 ablative laser among patients cutaneous leishmaniasis. Study design: Quasi-experimental study. Place duration study: Department Dermatology, Pakistan Emirates Military Hospital, Rawalpindi from 9th July 2020 to 8th January 2021. Methodology: Sixty (30 each group) diagnosed cases leishmaniasis by skin ...

Purpose: To develop a highly accurate molecular assay for evaluating the efficacy of metronidazole and some antifungal agents with meglumine antimoniate against L. infantum visceral leishmaniasis in different mouse tissues. Methods: The assay was performed with the Light-Cycler system using SYBR Green I and primers amplifying ca. 120-bp fragment from minicircles of the kinetoplast DNA (kDNA).Th...

the current treatment of choice for cutaneous leishmaniasis is either parenteral or intralesional antimonial compounds. each of these treatments has its own downfalls which include toxic side effects with the parentral injection and pain at the site of injection with the intralesional injection. in recent years, there has been more focus on paromomycin as an alternative drug; however, current d...

background cutaneous leishmaniasis (cl) is an endemic disease in iran. pentavalent antimonials including meglumine antimoniate (ma) are still the gold standard treatment. trichloroacetic acid (tca) is used in treatment of acne scar, photodamaged skin, and some other dermatologic diseases. considering the tca potential to induce collagen synthesis and its efficacy in the treatment of papular cl ...

BACKGROUND Therapeutic response in infectious disease involves host as well as microbial determinants. Because the immune and inflammatory response to Leishmania (Viannia) species defines the outcome of infection and efficacy of treatment, immunomodulation is considered a promising therapeutic strategy. However, since Leishmania infection and antileishmanial drugs can themselves modulate drug t...